Context:
Associations of major lipids and apolipoproteins with the risk of vascular disease have not been reliably quantified.
Objective:
To assess major lipids and apolipoproteins in vascular risk.
Design, Setting, And Participants:
Individual records were supplied on 302,430 people without initial vascular disease from 68 long-term prospective studies, mostly in Europe and North America. During 2.79 million person-years of follow-up, there were 8857 nonfatal myocardial infarctions, 3928 coronary heart disease [CHD] deaths, 2534 ischemic strokes, 513 hemorrhagic strokes, and 2536 unclassified strokes.
Main Outcome Measures:
Hazard ratios (HRs), adjusted for several conventional factors, were calculated for 1-SD higher values: 0.52 log(e) triglyceride, 15 mg/dL high-density lipoprotein cholesterol (HDL-C), 43 mg/dL non-HDL-C, 29 mg/dL apolipoprotein AI, 29 mg/dL apolipoprotein B, and 33 mg/dL directly measured low-density lipoprotein cholesterol (LDL-C). Within-study regression analyses were adjusted for within-person variation and combined using meta-analysis.
Results:
The rates of CHD per 1000 person-years in the bottom and top thirds of baseline lipid distributions, respectively, were 2.6 and 6.2 with triglyceride, 6.4 and 2.4 with HDL-C, and 2.3 and 6.7 with non-HDL-C. Adjusted HRs for CHD were 0.99 (95% CI, 0.94-1.05) with triglyceride, 0.78 (95% CI, 0.74-0.82) with HDL-C, and 1.50 (95% CI, 1.39-1.61) with non-HDL-C. Hazard ratios were at least as strong in participants who did not fast as in those who did. The HR for CHD was 0.35 (95% CI, 0.30-0.42) with a combination of 80 mg/dL lower non-HDL-C and 15 mg/dL higher HDL-C. For the subset with apolipoproteins or directly measured LDL-C, HRs were 1.50 (95% CI, 1.38-1.62) with the ratio non-HDL-C/HDL-C, 1.49 (95% CI, 1.39-1.60) with the ratio apo B/apo AI, 1.42 (95% CI, 1.06-1.91) with non-HDL-C, and 1.38 (95% CI, 1.09-1.73) with directly measured LDL-C. Hazard ratios for ischemic stroke were 1.02 (95% CI, 0.94-1.11) with triglyceride, 0.93 (95% CI, 0.84-1.02) with HDL-C, and 1.12 (95% CI, 1.04-1.20) with non-HDL-C.
Conclusion:
Lipid assessment in vascular disease can be simplified by measurement of either total and HDL cholesterol levels or apolipoproteins without the need to fast and without regard to triglyceride.
Citing Articles
Beyond platelet activation: dysregulated lipid metabolism in defining risk and pathophysiology of VITT.
Stevens H, McFadyen J, Mellett N, Lynn D, Duong T, Giles C
Res Pract Thromb Haemost. 2025; 9(1):102677.
PMID: 40041449
PMC: 11879676.
DOI: 10.1016/j.rpth.2025.102677.
Repeated-Dose Toxicity of Lauric Acid and Its Preventive Effect Against Tracheal Hyper-Responsiveness in Wistar Rats with Possible Molecular Targets.
Figueiredo I, Martins A, Cavalcanti A, Fernandes J, Gomes L, Vieira M
Pharmaceuticals (Basel). 2025; 18(2).
PMID: 40006035
PMC: 11859213.
DOI: 10.3390/ph18020221.
Novel lipid profiles and atherosclerotic cardiovascular disease risk: insights from a latent profile analysis.
Wan H, Wu H, Wei Y, Wang S, Ji Y
Lipids Health Dis. 2025; 24(1):71.
PMID: 40001219
PMC: 11854406.
DOI: 10.1186/s12944-025-02471-3.
Epigenetic regulation in coronary artery disease: from mechanisms to emerging therapies.
Gao R, Liu M, Yang H, Shen Y, Xia N
Front Mol Biosci. 2025; 12:1548355.
PMID: 39959304
PMC: 11825346.
DOI: 10.3389/fmolb.2025.1548355.
Development and validation of a predictive model for carotid atherosclerosis in postmenopausal women.
Liu J, Zeng X, Ruan J, Kang Y, Lu Y, Li S
Sci Rep. 2025; 15(1):5079.
PMID: 39934244
PMC: 11814320.
DOI: 10.1038/s41598-025-89098-7.
Development of an atherosclerosis rabbit model to evaluate the hemodynamic impact of extracorporeal circulation.
Assmann A, Buschmann J, Reimers S, Karakas A, Weber E, Aubin H
Animal Model Exp Med. 2025; 8(3):523-533.
PMID: 39909868
PMC: 11904102.
DOI: 10.1002/ame2.12556.
U-shaped association between the non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio and mortality risk in obese adults: evidence from NHANES 1999-2018.
Lin Z, Yi T, Hu F, Chen J, Chen L
Front Cardiovasc Med. 2025; 11:1524465.
PMID: 39866802
PMC: 11759299.
DOI: 10.3389/fcvm.2024.1524465.
Beyond traditional metrics: evaluating the triglyceride-total cholesterol-body weight index (TCBI) in cardiovascular risk assessment.
Rezaee M, Kamrani F, Imannezhad M, Hashemi Shahri H, Saihood W, Rezvani A
BMC Cardiovasc Disord. 2025; 25(1):39.
PMID: 39849378
PMC: 11756170.
DOI: 10.1186/s12872-025-04500-6.
The relationship between non-HDL-C/HDL-C ratio and bone mineral density: an NHANES study.
Qi S, Peng B, Xu Z, Qiu D, Tan G
Front Nutr. 2025; 11():1486370.
PMID: 39839298
PMC: 11747152.
DOI: 10.3389/fnut.2024.1486370.
Impact of Lipid Parameters on Visual Acuity Change in Non-Arteritic Anterior Ischemic Optic Neuropathy.
Kemchoknatee P, Arjkongharn N, Pongpirul K
Clin Ophthalmol. 2024; 18:3791-3800.
PMID: 39712368
PMC: 11660657.
DOI: 10.2147/OPTH.S500368.
The association of HDL-cholesterol levels with incident major adverse cardiovascular events and mortality in 0.6 million individuals with type 2 diabetes: a population-based retrospective cohort study.
Lui D, Li L, Liu X, Xiong X, Tang E, Lee C
BMC Med. 2024; 22(1):586.
PMID: 39696353
PMC: 11657474.
DOI: 10.1186/s12916-024-03810-4.
Integrated exposomic analysis of lipid phenotypes: Leveraging GE.db in environment by environment interaction studies.
Rico A, Palmiero N, Ritchie M, Hall M
Pac Symp Biocomput. 2024; 30:535-550.
PMID: 39670394
PMC: 11694901.
Decoding the Lipid-Angiogram Link: Can Serum Lipid Profile Help Predict Your Clogged Arteries?.
Gupta S, Priyadarshi A, Beg M, Rabbani M
Cureus. 2024; 16(11):e73454.
PMID: 39664144
PMC: 11633823.
DOI: 10.7759/cureus.73454.
Association of cumulative non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio with the risk of cardiometabolic disease.
Liu L, Liu S, Liao Y, Zhang X, Wang M, Lin L
Front Cardiovasc Med. 2024; 11:1500025.
PMID: 39635266
PMC: 11614763.
DOI: 10.3389/fcvm.2024.1500025.
Predictive nomogram for ischemic stroke risk in clear cell renal cell carcinoma patients.
Wen J, Rong Y, Kang Y, Lv D, Cui F, Zhou H
Sci Rep. 2024; 14(1):30162.
PMID: 39627344
PMC: 11615042.
DOI: 10.1038/s41598-024-82072-9.
Temporal changes in lipid concentrations and the prevalence of dyslipidemia among individuals with diabetes, prediabetes, and normal blood glucose from 2011 to 2015.
Zhao M, Cheng Y, Li M, Zhang W, Ji J, Lu F
Lipids Health Dis. 2024; 23(1):394.
PMID: 39605064
PMC: 11603987.
DOI: 10.1186/s12944-024-02375-8.
Proteome-wide association studies for blood lipids and comparison with transcriptome-wide association studies.
Zhang D, Gao B, Feng Q, Manichaikul A, Peloso G, Tracy R
HGG Adv. 2024; 6(1):100383.
PMID: 39543875
PMC: 11650301.
DOI: 10.1016/j.xhgg.2024.100383.
Socioeconomic inequalities and dyslipidaemia in adult population of the Ravansar Non-Communicable Disease Cohort Study: the role of sex and age.
Izadi N, Yari-Boroujeni R, Soofi M, Niknam M, Amiri P, Najafi F
BMJ Open. 2024; 14(11):e085035.
PMID: 39496368
PMC: 11535690.
DOI: 10.1136/bmjopen-2024-085035.
The role of lipase maturation factor 1 in hypertriglyceridaemia and atherosclerosis: An update.
Dabravolski S, Churov A, Sukhorukov V, Kovyanova T, Beloyartsev D, Lyapina I
SAGE Open Med. 2024; 12:20503121241289828.
PMID: 39483624
PMC: 11526315.
DOI: 10.1177/20503121241289828.
Retrospective cohort evaluation study in terms of cardiovascular and metabolic diseases in chronic hepatitis B patients.
Yakut A
Front Endocrinol (Lausanne). 2024; 15:1426196.
PMID: 39421537
PMC: 11484011.
DOI: 10.3389/fendo.2024.1426196.